about
Toxic epidermal necrolysisSézary Syndrome and Atopic Dermatitis: Comparison of Immunological Aspects and TargetsAngioimmunoblastic T-Cell Lymphoma Mimicking Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome)Human TH9 cells are skin-tropic and have autocrine and paracrine proinflammatory capacity.Primary localization and tumor thickness as prognostic factors of survival in patients with mucosal melanoma.IL-4-mediated fine tuning of IL-12p70 production by human DC.Is cyclophotocoagulation an option in the management of glaucoma secondary to Fuchs' uveitis syndrome?IL-4 abrogates T(H)17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cellsMelanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth.ROS-induced ATF3 causes susceptibility to secondary infections during sepsis-associated immunosuppression.TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma.Novel therapies for cutaneous T-cell lymphoma: what does the future hold?Recent advances in primary cutaneous T-cell lymphoma.Inpatient Treatment for Severe Nonsurgical Dermatological Disorders: Prevalence, Care Infrastructure and Reimbursement in Switzerland.Adverse cutaneous drug eruptions: current understanding.Banana leaves as an alternative wound dressing.Early clinical manifestations of Sézary syndrome: A multicenter retrospective cohort study.High levels of lung resident CD4+CD28null cells in COPD: implications of autoimmunity.Interleukin-1 receptor antagonist (anakinra) for Schnitzler syndrome.Immunoglobulin e-mediated anaphylaxis to sesameCutaneous Oncology: From Research to Diagnosis and Management.Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma.Cutaneous innate immune sensing of Toll-like receptor 2-6 ligands suppresses T cell immunity by inducing myeloid-derived suppressor cells.Incidental finding of lamellar calcification of the falx cerebri leading to the diagnosis of gorlin-goltz syndrome.Disseminated Primary Cutaneous CD8+ Small/Medium-sized Pleomorphic T-cell Lymphoma Responding to Hydroxychloroquine.TLR4 as a negative regulator of keratinocyte proliferation.Nodular malignant melanoma and multiple cutaneous neoplasms under immunosuppression with azathioprine.Residents' corner September 2011. Residents' editorial choice.Natural Staphylococcus aureus-derived peptidoglycan fragments activate NOD2 and act as potent costimulators of the innate immune system exclusively in the presence of TLR signals.Tinea incognito hidden under apparently treatment-resistant pemphigus foliaceus.Efficacy of bath psoralen plus ultraviolet A (PUVA) vs. system PUVA in psoriasis: a prospective, open, randomized, multicentre study.Alagille syndrome associated with myelinated retinal nerve fibers.Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients.Palmar-plantar erythrodysesthesia secondary to sunitinib treatment resulting in necrotic foot syndrome aggravated by background diabetic vascular disease.Classic Mediterranean Kaposi's sarcoma regression with sirolimus treatment.Toll-like receptor 2 ligands promote chronic atopic dermatitis through IL-4-mediated suppression of IL-10.Expression of inflammatory cytokines in psoriatic nails.Skin Test Reactivity to Hymenoptera Venom after Venom Immunotherapy Correlates Inversely with the IgG/IgE Ratio.Clinical Disease Patterns in a Regional Swiss Cohort of 34 Pyoderma Gangrenosum Patients.PD1-positive tumor-infiltrating lymphocytes are associated with poor clinical outcome after pulmonary metastasectomy for colorectal cancer.
P50
Q26745232-1E7E291A-6B74-4641-AAD0-0C071793FC5EQ26746551-A644C6E5-4606-4275-BD9F-F271F1F4250FQ33781845-C91F53A7-0038-4A0A-995E-52D77617AAABQ33915697-090A4E73-31F1-45DF-9CC1-2B0E7C61B6C1Q34482926-25964288-7A10-465B-913D-33B7A3523849Q34857748-494E5736-E6BC-4CDF-B693-F145C95F9F45Q35081922-C07395B5-E9BE-4581-A6EC-55BF5683C55FQ35129052-A48E6A8C-F082-4DF4-8B06-9DDCD645C3D1Q36429062-0445A623-7BB9-4924-B625-D1EA78222166Q36564435-47E7C5F2-D208-4D34-A3C1-F69255F456FBQ37025122-05A2E189-359C-4955-87BD-87328895485AQ38176398-5584DBA3-8642-45D5-9DB3-CE290A9BBD19Q38320767-CAAC6674-CB4D-4495-8864-027459F5DAE4Q38387350-93ACAD26-6AAD-4F81-BCFF-2E0DD4158BE0Q38629246-56C93E12-067A-4D7E-9FE3-2082CA466C13Q38866071-235F1893-E905-4441-B21A-F9E4AE01EB80Q39435763-853D95CB-1ECD-4A15-AE69-BDE1FDB64D76Q39444602-C1B6CD84-856C-47C6-955B-30F2C075DEA5Q40118761-F25D8A59-CF6C-4B8F-9351-ED2072C035ACQ40617730-2811CE05-26A4-458B-8748-29212C9E9FCCQ40637955-E72E1CDB-00C6-41FF-85A4-4DCB4EB952D3Q41204382-FDE8D3EC-1121-4003-BC38-A47E6ADA2837Q41629393-EE142EF3-B578-4078-BD37-039754F14077Q41857270-AAD33FBF-E5A4-49B9-8B5B-77AF5BADD49AQ41919723-C7BB0C9C-C776-4586-83AA-638DEB6CD8A4Q42370733-6FF85451-7EF8-42E2-8E6A-F42B9A4F105BQ42455952-ACD93D29-7F31-4506-9E9C-25C0FE3B9150Q42494290-6D6FF7E6-C68B-4CE3-8555-0B6152D275AEQ43044974-FBF2C609-CBA1-4B33-91FA-0541E52A2CFBQ44829631-9D5FB9B9-76DF-404E-881B-52D4E6D13369Q45839560-04D7DCC2-77AF-4D5A-8748-B39A3D17EC1DQ45942902-5E9B135B-318C-41C8-8AC4-6766A79163E8Q46038962-0B53430C-4D89-4E1F-9C65-A10EC0093681Q46423695-74133B01-A1B2-4B0E-BAC3-C4E835743394Q46587304-29B8389D-80A5-46DF-B367-C4E75CCFF7C0Q46683594-6978ACE5-F849-40AC-9E6F-3FE9FE8C9AB1Q47274718-834ACE09-BB3A-4A5F-9D39-EB749D36C8C3Q47410171-702862BC-E6E0-4842-B267-168DB4EDC39CQ47410269-B15F88F2-8225-4BFE-8744-00F2ADE2F48AQ47938015-9DC425CC-82AE-4B43-8683-1D3DD53EDD00
P50
description
Bulgarian dermatologist
@en
Bulgarian dermatologist
@en-ca
Bulgarian dermatologist
@en-gb
bulgarische Hautärztin
@de
dermatoloog
@nl
dermatóloga búlgara
@es
طبيبة أمراض جلدية بلغارية
@ar
name
Emmanuella Guenova
@ast
Emmanuella Guenova
@de
Emmanuella Guenova
@en
Emmanuella Guenova
@es
Emmanuella Guenova
@fr
Emmanuella Guenova
@nl
Emmanuella Guenova
@sl
type
label
Emmanuella Guenova
@ast
Emmanuella Guenova
@de
Emmanuella Guenova
@en
Emmanuella Guenova
@es
Emmanuella Guenova
@fr
Emmanuella Guenova
@nl
Emmanuella Guenova
@sl
prefLabel
Emmanuella Guenova
@ast
Emmanuella Guenova
@de
Emmanuella Guenova
@en
Emmanuella Guenova
@es
Emmanuella Guenova
@fr
Emmanuella Guenova
@nl
Emmanuella Guenova
@sl
P108
P214
P227
P106
P21
P214
P227
P31
P3829
P496
0000-0001-5478-8735
P569
1979-01-01T00:00:00Z
P735
P7859
viaf-80641621